Mode
Text Size
Log in / Sign up

FEES Dysphagia Index (FDI) derivation and validation in hospitalized neurological patientsA new swallowing test may better predict pneumonia risk in hospitalized brain patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the FDI-C as a bedside tool for dysphagia risk assessment in neurological inpatients, noting its observational validation.

This single-center, retrospective cohort study derived and validated the FEES Dysphagia Index (FDI) in two cohorts of hospitalized neurological patients (n=1,257 and n=1,686). The comparator was the Worst Penetration-Aspiration Scale (PAS) score. The primary outcome was FDI-C performance for clinical outcomes.

For hospital-acquired pneumonia, FDI-C had an AUC of 0.70 versus Worst PAS AUC of 0.60 (p<0.001). For mortality, FDI-C AUC was 0.71 versus Worst PAS AUC of 0.62 (p=0.040). For restricted oral intake, FDI-C AUC was 0.90 versus Worst PAS AUC of 0.74 (p<0.001). FDI-C mapped linearly onto ordinal FOIS values (proportional odds RCS p=0.99). It reconstructed clinician oral intake recommendations with AUC up to 0.93.

Safety and tolerability were not reported. Key limitations include retrospective design, single-center setting, and selection bias addressed but not eliminated. The study is observational; association does not imply causation.

Practice relevance is that FDI-C is a bias-resilient, bedside-calculable score for clinical decision support. However, generalizability beyond neurological inpatients is uncertain, and absolute risk reduction was not reported.

For people hospitalized with neurological conditions like stroke or Parkinson's, trouble swallowing is a common and dangerous complication. It can lead to pneumonia if food or liquid goes into the lungs, and it's a major reason patients stay in the hospital longer or don't recover as well. Doctors use tests to assess this risk, but they're looking for better ways to spot who's most in danger.

This research looked at over 2,900 hospitalized neurological patients and compared a new scoring method, called the FEES Dysphagia Index-Clinical (FDI-C), against a commonly used measure. The FDI-C was better at predicting who would develop hospital-acquired pneumonia and who might die. It also did a better job predicting when patients would need their diet restricted. The score can be calculated at the bedside and seems to hold up even with some biases in patient selection.

However, this was a single-hospital study looking back at past records, not a forward-looking trial. That means it shows an association, not proof that using the score causes better outcomes. The results might not apply to all hospitals or patients outside neurological wards. The study didn't report absolute numbers for how many patients got pneumonia or died, so the real-world impact isn't clear yet. Still, for clinicians, it points to a promising tool that could help make quicker, safer decisions about feeding and care.

What this means for you:
A new swallowing score predicted pneumonia and death better than a standard test in brain patients.

Study Details

Study typeCohort
Sample sizen = 1,257
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Multi-consistency testing during flexible endoscopic evaluation of swallowing (FEES) is clinically necessary but introduces selection bias: worst scores inflate severity because the number of consistencies tested covaries with disease severity. In this retrospective observational study of hospitalized neurological patients, we derived and validated the FEES Dysphagia Index (FDI) in two temporally independent cohorts (Cohort 1: 2013-2018, N=1,257; Cohort 2: 2021-2025, N=1,686) from a single center. FDI-S averages Penetration-Aspiration Scale (PAS) scores across tested consistencies (0-100 scale); FDI-E uses Yale Pharyngeal Residue scores; FDI-C combines both. Selection bias was quantified using sequential branching-tree inverse probability weighting (IPW). Worst PAS overestimated severity by 24%; FDI deviated by <2%. FDI-C was significantly superior to Worst PAS for hospital-acquired pneumonia (HAP; AUC 0.70 vs. 0.60, p<0.001), mortality (0.71 vs. 0.62, p=0.040), and restricted oral intake (0.90 vs. 0.74, p<0.001), and statistically equivalent to clinician-rated severity. FDI-C mapped linearly onto ordinal Functional Oral Intake Scale values (FOIS; proportional odds RCS p=0.99). With functional status and diagnosis, FDI-C reconstructed the clinician's oral intake recommendation with AUC up to 0.93. The FDI-C-mortality relationship was sigmoidal with a clinically relevant transition zone between ~50 and ~85. FDI-C is a bias-resilient, bedside-calculable score with interval-scale properties that captures expert clinical judgment, suitable as both a clinical decision support tool and a continuous research endpoint.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.